{
  "concept": "Engineered ruthenium complexes may selectively target histidine-rich sequences in the cardiac sodium channel DIII-DIV linker region, potentially modulating fast inactivation kinetics through reversible metal-ligand coordination. This approach could provide controlled channel conductance modulation distinct from oxidative mechanisms, offering a novel therapeutic strategy for chemotherapy-induced arrhythmias.",
  "rationale": [
    {
      "statement": "Chemotherapy-induced cardiotoxicity represents a critical unmet medical need, with arrhythmia incidence reaching 15.8% across cancer treatments. Doxorubicin specifically enhances late sodium current in cardiac myocytes, establishing Nav1.5 dysfunction as a direct pathophysiological mechanism requiring targeted intervention.",
      "supporting_dois": [
        "10.1016/j.heliyon.2024.e34176",
        "10.1080/1120009x.1990.11739029",
        "10.1093/eurheartj/ehaa006",
        "10.1097/00005344-199111000-00009",
        "10.1111/bph.13791",
        "10.1111/bph.14104",
        "10.1161/hc0402.102661",
        "10.1161/jaha.118.010101",
        "10.1254/fpj.23094",
        "10.1517/13543776.18.1.1",
        "10.15829/1728-8800-2020-2417",
        "10.29001/2073-8552-2020-35-1-13-21",
        "10.7759/cureus.41287"
      ]
    },
    {
      "statement": "The Nav1.5 DIII-DIV linker contains the IFM motif critical for fast inactivation and features solvent-accessible histidine clusters confirmed by cryo-EM structures. This region represents a structurally validated, functionally essential target for selective metal coordination.",
      "supporting_dois": [
        "10.1006/bbrc.1997.6510",
        "10.1016/s0006-3495(91)82269-x",
        "10.1016/s0006-3495(96)79329-3",
        "10.1016/s0008-6363(99)00064-4",
        "10.1039/c3mt00026e",
        "10.1073/pnas.1114748109",
        "10.1073/pnas.2416181122",
        "10.1073/pnas.71.10.3936",
        "10.1073/pnas.89.22.10905",
        "10.1073/pnas.89.22.10910",
        "10.1074/jbc.m806871200",
        "10.1085/jgp.109.5.607",
        "10.1085/jgp.200308929",
        "10.1085/jgp.201912434",
        "10.1126/science.1321496"
      ]
    },
    {
      "statement": "Ruthenium complexes demonstrate exceptional stability in biological environments through tridentate ligands and kinetic inertness. The tunable ligand sphere enables precise control of binding kinetics, cellular localization, and tissue specificity through chelating ligands and functional group modifications.",
      "supporting_dois": [
        "10.1002/chem.201702862",
        "10.1002/cmdc.201100053",
        "10.1002/cplu.201200268",
        "10.1007/s00775-014-1187-5",
        "10.1016/j.ijbiomac.2023.126666",
        "10.1021/acs.inorgchem.1c01083",
        "10.1021/acs.inorgchem.4c00922",
        "10.1021/acs.inorgchem.4c01727",
        "10.1021/acs.jpcb.0c02186",
        "10.1021/ic00010a024",
        "10.1021/ic502051y",
        "10.1021/jm0490742",
        "10.1021/jp109530f",
        "10.1021/om070219n",
        "10.1021/om980071v",
        "10.1039/c0dt00469c",
        "10.1039/c3ce41920g",
        "10.1039/c4ce01214c",
        "10.1039/c5dt04781a",
        "10.1039/c7cc02989f",
        "10.1039/c9ra05507j",
        "10.1039/d0dt02527e",
        "10.1039/dt9820000095",
        "10.1080/07391102.2019.1683071",
        "10.1246/bcsj.53.82",
        "10.1246/cl.2008.906",
        "10.1364/up.2022.tu4a.4",
        "10.1595/147106708x255987"
      ]
    },
    {
      "statement": "Endogenous metal ions like Zn2+ modulate cardiac sodium channels through conformational changes rather than pore blockade, while ruthenium compounds demonstrate channel modulation capabilities. These precedents establish that engineered ruthenium complexes can achieve selective, reversible binding to target histidine residues.",
      "supporting_dois": [
        "10.1002/chem.200900699",
        "10.1002/chem.201100279",
        "10.1016/s0006-3495(91)82269-x",
        "10.1016/s0014-5793(99)01260-0",
        "10.1016/s0022-3565(24)38291-6",
        "10.1021/acs.inorgchem.4c00665",
        "10.1021/acs.jcim.9b00806",
        "10.1021/acs.jmedchem.6b00600",
        "10.1021/acs.jpcb.0c02186",
        "10.1021/bi0017778",
        "10.1021/ic500387u",
        "10.1021/ja060515b",
        "10.1038/s44319-023-00050-0",
        "10.1038/sj.bjp.0701854",
        "10.1039/c3mt00026e",
        "10.1039/c3ra23089a",
        "10.1039/c5dt04747a",
        "10.1039/c5ra08602g",
        "10.1039/c8nr07259k",
        "10.1039/d0cc06974d",
        "10.1073/pnas.71.10.3936",
        "10.1085/jgp.101.2.153",
        "10.1085/jgp.102.6.1031",
        "10.1085/jgp.117.3.253",
        "10.1085/jgp.80.4.485",
        "10.1085/jgp.97.1.117",
        "10.1085/jgp.97.1.89",
        "10.1093/protein/4.1.57",
        "10.1113/jphysiol.1973.sp010417",
        "10.1113/jphysiol.1984.sp015011",
        "10.1113/jphysiol.2005.101089"
      ]
    },
    {
      "statement": "Advanced delivery strategies including nanoparticle formulation, cardiac-targeting ligands, and receptor-mediated uptake enable tissue-specific accumulation. Comprehensive validation frameworks spanning molecular binding assays to in vivo telemetric monitoring provide robust experimental pathways for therapeutic development.",
      "supporting_dois": [
        "10.1002/0471141755.ph1114s65",
        "10.1002/adfm.202204666",
        "10.1002/adfm.202303658",
        "10.1002/cmmi.1501",
        "10.1016/j.bpj.2020.01.012",
        "10.1016/j.celrep.2015.09.023",
        "10.1016/j.jmb.2013.06.036",
        "10.1016/j.jphs.2018.07.011",
        "10.1016/j.vascn.2015.05.002",
        "10.1016/j.yjmcc.2017.10.002",
        "10.1016/s0008-6363(01)00341-8",
        "10.1021/acsapm.4c00494",
        "10.1021/bc200565v",
        "10.1021/bm400104b",
        "10.1021/ed200549g",
        "10.1021/mp200589z",
        "10.1021/nl2025882",
        "10.1038/s41467-020-20078-3",
        "10.1038/s41598-021-87402-9",
        "10.1038/srep25613",
        "10.1039/c7cc02988h",
        "10.1039/c7nr01582h",
        "10.1042/bio_2022_139",
        "10.1053/jhep.2002.33997",
        "10.1073/pnas.1700761114",
        "10.1073/pnas.2416181122",
        "10.1073/pnas.71.10.3936",
        "10.1080/21681163.2015.1081079",
        "10.1085/jgp.88.1.1",
        "10.1089/adt.2011.414",
        "10.1096/fasebj.6.9.1612296",
        "10.1124/molpharm.120.000048",
        "10.1126/sciadv.abf2400",
        "10.1126/science.aal4326",
        "10.1126/scitranslmed.3002588",
        "10.1152/ajpcell.00649.2008",
        "10.1152/ajpheart.00556.2014",
        "10.1155/2003/372913",
        "10.1155/2018/6067096",
        "10.1161/01.cir.94.10.2641",
        "10.1177/2211068215623209",
        "10.1371/journal.pone.0015568",
        "10.1385/1-59259-052-7:189",
        "10.1385/1-59259-679-7:299",
        "10.1517/14728222.11.4.557",
        "10.22489/cinc.2017.035-307",
        "10.22489/cinc.2022.400",
        "10.30629/0023-2149-2023-101-9-10-454-466",
        "10.3389/fphar.2021.738260",
        "10.3389/fphar.2021.738460",
        "10.3389/fphys.2013.00358",
        "10.3389/fphys.2017.00668",
        "10.3390/biom13121690",
        "10.3390/biomedicines12061212",
        "10.3390/ph16060824",
        "10.3390/ph6030295",
        "10.3390/pharmaceutics15082107",
        "10.3390/s20143867",
        "10.3791/1739",
        "10.3791/1739-v",
        "10.3791/60895",
        "10.3791/60895-v",
        "10.3791/62386",
        "10.3791/62386-v"
      ]
    }
  ]
}